News

FAP affects an estimated one in 10,000 people across the world and is associated with a near 100% risk of colon cancer if untreated. Additionally, the company announced

Aerie is focused on the discovery, development and commercialization of first-in-class therapies for patients with glaucoma and other diseases of the eye. GrayBug develops microparticle controlled release drug

As part of the deal, a Phase I/II trial will be conducted to evaluate the safety and efficacy of MedImmune’s durvalumab (MEDI4736) in combination with Mirati’s mocetinostat in

The company secured final approval from the US Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA)for this product to treat GERD. According to IMS

The randomized, crossover study Phase IIb trial is designed to evaluate the safety, tolerability and efficacy of three different doses of ALLN-177 for reducing urinary oxalate excretion in

This agreement will complement Flexion’s existing manufacturing relationship with Evonik Corporation and create redundant supply for FX006, which is an intra-articular (IA) sustained-release steroid for the treatment of

Minerva Biotechnologies discovered a naturally occurring, primitive growth factor that continues this reprogramming to an even earlier, embryonic-like point called the ‘naïve’ state. Scientists believe that because these

Insulin glargine 300 units/ml is indicated for the treatment of diabetes mellitus in adults and is a novel formulation of the glargine molecule Lantus (insulin glargine 100 units/mL)

The company noted that in a Phase I trial, low-dose veltuzumab, as a single agent, produced an objective response rate of 55% in 38 response-assessable patients with relapsed